Identification of epidermal growth factor receptor-derived peptides immunogenic for HLA-A2(+) cancer patients.
Identification of epidermal growth factor receptor-derived peptides immunogenic for HLA-A2(+) cancer patients.
复制标题
HLA-A2（+）癌症患者的表皮生长因子受体衍生的肽免疫原性的鉴定。
DOI：
10.1038/sj.bjc.6601728
复制
发表时间：
2004-04-19
影响因子：
8.8
通讯作者：
中科院分区：
文献类型：
--
作者：
表皮生长因子受体（EGFR）是癌症治疗最合适的靶分子之一，因为它在约三分之一的上皮癌中表达相对较高，与肿瘤进展相关。在EGFR靶向治疗方面，抗体和酪氨酸激酶抑制剂已得到深入研究，新型EGFR酪氨酸激酶抑制剂ZD1839已被批准作为抗癌药物，还有许多药物正在进行临床试验。此外，细胞毒性 T 淋巴细胞 (CTL) 定向表位肽可能是另一类可用于 EGFR 靶向治疗的化合物。然而，目前还没有关于EGFR的CTL定向肽的信息。因此，从开发基于肽的癌症治疗的角度来看，本研究旨在确定HLA-A2+上皮癌患者的细胞和体液免疫识别的EGFR衍生肽。我们在此报告了在位置479-488和位置1138-1147发现了两种此类类型的EGFR衍生肽，这两种肽均被大多数患者的血清（IgG）识别，并且还具有诱导针对患者外周血单核细胞（PBMC）中EGFR阳性肿瘤细胞的HLA-A2限制性肽特异性CTL的能力。 上皮癌患者。这些结果可能为针对HLA-A2+癌症患者开发基于EGFR的免疫疗法提供科学依据。
Epidermal growth factor receptor (EGFR) is one of the most appropriate target molecules for cancer therapy because of its relatively high expression in about one-third of all epithelial cancers in correlation with neoplasmic progression. With respect to EGFR-targeted therapies, antibodies and tyrosine-kinase inhibitors have been intensively studied, a novel EGFR-tyrosine-kinase inhibitor ZD1839 has been approved as an anticancer drug, and many other agents are now under clinical trial. In addition, cytotoxic T lymphocyte (CTL)-directed epitope peptides could be another class of compounds useful in EGFR-targeted therapies. However, there is presently no information on CTL-directed peptides of EGFR. Therefore, from the viewpoint of development of peptide-based cancer therapy, this study was intended to determine the EGFR-derived peptides recognised by both cellular and humoral immunities in HLA-A2+ epithelial cancer patients. We herein report finding of two such types of EGFR-derived peptides at position 479–488 and 1138–1147, both of which were recognised by the majority of patients' sera (IgG), and also possessed the ability to induce HLA-A2-restricted peptide-specific CTLs against EGFR-positive tumour cells in peripheral blood mononuclear cells (PBMCs) of epithelial cancer patients. These results may provide a scientific basis for the development of EGFR-based immunotherapy for HLA-A2+ cancer patients.
登录
查看更多内容
影响因子：
56.9
作者：
COUSSENS, L;YANGFENG, TL;ULLRICH, A
通讯作者：
ULLRICH, A
影响因子：
2.8
作者：
Noguchi, M;Kobayashi, K;Noda, S
通讯作者：
Noda, S
影响因子：
64.8
作者：
YAMAMOTO, T;IKAWA, S;TOYOSHIMA, K
通讯作者：
TOYOSHIMA, K
影响因子：
3.9
作者：
Tsuda, N;Mochizuki, K;Kamura, T
通讯作者：
Kamura, T
影响因子：
3
作者：
Parkar, MH;Kuru, L;Olsen, I
通讯作者：
Olsen, I